BRM-421

Summary

Brm-421 (CHEMBL5315015) is a phase-3 clinical-stage unknown; indicated across 1 condition including dry eye syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 1 condition
• Clinical trials: 2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5315015
Name	BRM-421
Type	Unknown
Max phase	3

Also known as: Brm-421, BRM-424, Brm421, BRM424, BRM-421

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
dry eye syndrome	3	MONDO:0006733	EFO:1000906

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE2/PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04343287	PHASE2/PHASE3	COMPLETED	Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment
NCT03066219	PHASE2	COMPLETED	Safety and Efficacy of BRM421 for Dry Eye Syndrome

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).